Personnel Information

写真a

KURATA Morito


Job title

Junior Associate Professor

Laboratory Phone number

+81-3-5803-5176

Graduating School 【 display / non-display

  • Fukui Medical University, Faculty of Medicine, 2003.03, Graduated

Graduate School 【 display / non-display

  • Tokyo Medical and Dental University, Doctor's Course, 2007.03, Completed

Campus Career 【 display / non-display

  • 2007.04
    -
    2013.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Assistant Professor
  • 2013.04
    -
    2018.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Junior Associate Professor
  • 2018.04
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Comprehensive Pathology, Junior Associate Professor

Research Areas 【 display / non-display

  • Pathological medical chemistry

  • Experimental pathology

 

Published Papers & Misc 【 display / non-display

  • Kitagawa M, Kurata M, Onishi I, Yamamoto K. Bone marrow niches in myeloid neoplasms. Pathology international. 2019.11; ( PubMed, DOI )

  • Yamamoto K, Abe S, Honda A, Hashimoto J, Aizawa Y, Ishibashi S, Takemura T, Hanagata N, Yamamoto M, Miura O, Kurata M, Kitagawa M. Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma. Laboratory investigation; a journal of technical methods and pathology. 2019.09; ( PubMed, DOI )

  • Nogawa Daichi, Gulinisha Aihemaiti, Yamamoto Akiko, Onishi Iichiroh, Kurata Morito, Miyasaka Naoyuki, Yamamoto Kohei, Kitagawa Masanobu. Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma CANCER SCIENCE. 2018.12; 109 503.

  • Kurata Morito, Yamamoto Kohei, Kitagawa Masanobu. Controllable NRAS expression system and analysis of different signals CANCER SCIENCE. 2018.12; 109 895.

  • Yamamoto Kohei, Abe Shinya, Kurata Morito, Honda Ayaka, Yamamoto Masahide, Kitagawa Masanobu. Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma CANCER SCIENCE. 2018.12; 109 494.

display all >>

Conference Activities & Talks 【 display / non-display

  • 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 立澤 杏奈, 峰尾 竜徳, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本病理学会会誌 2019.04.01

  • 山本 浩平, 阿部 晋也, 本田 彩華, 山本 正英, 三浦 修, 倉田 盛人, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本病理学会会誌 2019.04.01

  • 野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸. 卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma). 日本癌学会総会記事 2018.09.01

  • 倉田 盛人, 山本 浩平, 北川 昌伸. NRAS発現調整可能システムとシグナルの解析(Controllable NRAS expression system and analysis of different signals). 日本癌学会総会記事 2018.09.01

  • 山本 浩平, 阿部 晋也, 倉田 盛人, 本田 彩華, 山本 正英, 北川 昌伸. ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma). 日本癌学会総会記事 2018.09.01